Office

Level 9, Suite 1, 68 Pitt Street,
Sydney, NSW, 2000, Australia

+61 (02) 8964 7401

info@actinogen.com

Social Media

Actinogen Medical logo

“Focused on the treatment of Alzheimer’s disease
and mild cognitive impairment.”

Actinogen Medical is a publicly listed (ASX: ACW) clinical-stage biotechnology company undertaking research in Alzheimer’s disease and other age-related neurodegenerative diseases.

Actinogen is developing a novel drug, Xanamem™, which has been specifically designed to block the production of cortisol in the brain.

Find out more

Actinogen has successfully completed all the necessary early phase studies to confirm that Xanamem™ is well tolerated with an acceptable safety profile.

Actinogen is well advanced with plans to initiate a Phase II efficacy and safety study in mild Alzheimer’s disease patients in the second quarter of 2016. This study will be run in Australia, the United Kingdom, and the United States, under an FDA approved IND.

Find out more

“Positive trial results confirm Xanamem™ is effectively delivered to the brain.”

– Dr. Bill Ketelbey, 29 September, 2015

0.0520 0.0000 (0.00%) 
Dec 1 – Close | 
ASX data delayed by 20 mins | Currency in AUD

dummy-chart-purple
Go to Investor Centre

Subscribe to our newsletter

Are you an Investor?  Yes